Reshaping Vision
POSSIBILITIES

As agile partners to the eye care community, we see every day as an opportunity to disrupt conventional thinking in pursuit of vision without limitations.
That is why we reimagined existing and well-studied molecules to create a unique prescription eye drop for presbyopia.

what is presbyopia

Presbyopia is the gradual loss of your eye’s ability to focus on near objects. This progressive condition begins to affect most people sometime after the age of 40, impacting more than 1.8 billion people worldwide.

our solution

CSF-1 is our novel formulation of low-dose pilocarpine and a proprietary vehicle without preservatives. Now nearing completion of Phase 3 clinical trials, CSF-1 is designed to provide the optimal balance of efficacy, safety and comfort.

company updates

Apr 23 2022

Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 21 2022

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Apr 12 2022

Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 7 2022

Orasis Pharmaceuticals Appoints Teresa (Tes) Ignacio, M.D. as Vice President, Medical Affairs

Mar 15 2022

Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials  for Presbyopia Candidate

Oct 3 2021

Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan

Apr 26 2021

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

Oct 28 2020

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

Sept 10 2020

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

May 11 2020

Chief executive officer Elad Kedar spoke with the OIS Podcast on his strategy for success in completing a Phase 2b clincal study and how Orasis is now preparing to move into Phase 3 with our product candidate CSF-1. Chairman Jeffry Weinhuff also offers insights into Visionary Ventures’ investment decisions. Listen to the full podcast here.

Jan 28 2020

Chief executive officer, Elad Kedar, spoke with the Bio Report podcast on the potential of CSF-1 to treat presbyopia or age-related farsightedness and the eye drop’s recent positive Phase 2b study results. Listen to the full podcast here.

Nov 14 2019

Following the positive results from our Phase 2b U.S. clinical trial of CSF-1, Orasis CEO Elad Kedar spoke with Healio Ocular Surgery News about the eye drop and its potential as a meaningful treatment for people with presbyopia. Watch the full interview

Oct 10 2019

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

May 29 2019

Orasis CEO Elad Kedar was interviewed by Ophthalmology Innovation Summit (OIS) TV about our corrective eye drop for the treatment of presbyopia and progress in our Phase 2b clinical study

Apr 8 2019

CEO Elad Kedar Discusses Our Ongoing Phase 2b Clinical Study of CSF-1 and the Eye Drop’s Treatment Effect with Healio

Mar 27 2019

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia